Intermittent fasting

Studies of intermittent fasting in people

53 studies gave intermittent fasting to people and measured what changed

What changedDesignPeopleSource

down: Decreases body weight-2.7 kg (95% CI -2.9 to -2.4)

down: Decreases blood pressure

down: Decreases mean glucose

Randomized trial4 weeks68 peopleWomenadultsAcross the 16:8 and 5:2 groups with overweight or obesityObesity (Silver Spring, Md.), Oct 28, 2026

down: Decreases body weight−6.83 ± 4.26 kg (−7.02%)

down: Decreases body fat mass−5.38 ± 3.13 kg (−13.61%)

down: Decreases soft lean mass−1.44 ± 1.88 kg (−2.68%)

Trial62-day35 people20 males (57.10%) and 15 females (42.90%)average age of 36.23 ± 8.98 yearsIndividuals with obesity in ChinaFrontiers in nutrition, Sep 9, 2026

no change: Has no effect on thigh muscle area

no change: Has no effect on intermuscular adipose tissue

Randomized triala month-long66 peopleGeneral populationClinical radiology, Aug 22, 2026

down: Decreases body mass

Randomized trial4 weeks80 peopleMenyoung adultAlternate-day fasting protocolPreprints.org, Aug 19, 2026

down: Decreases diabetes medication burden67%

up: Increases type 2 diabetes remission14%

Randomized trial12 months57 peoplePatient cohortsADA Scientific Sessions 2026 abstract, Jun 5, 2026

down: Decreases body weight

down: Decreases fat mass

down: Decreases fat-free mass

Review of trials1,833 people pooled<30 yearsGeneral population; Midlife adultsNutrients, Jun 3, 2026

down: Decreases body weight-1.025 kg (95% CI: -0.09 to -1.96 kg; p = 0.03)

Randomized trial12 weeks20 peoplemean age 53 ± 9.5 yearsMidlife adults; Patient cohortsClinical nutrition ESPEN, May 4, 2026

no change: Has no effect on remissionOR 1.5, 95% CI: 0.6–4.3

Randomized trial12 weeks120 people50.0 years (SD = 7.7)Adults aged 18–60 years with less than 5 years duration of type 2 diabetes diagnosisEndocrinology, diabetes & metabolism, Apr 12, 2026

down: Decreases body weighttwofold more weight and fat loss

no change: Has no effect on muscle strength

no change: Has no effect on testosterone

Randomized trial8 weeks20 peopleMen20-30Obese males undergoing resistance trainingJournal of obesity, Feb 19, 2026

up: Increases CD8+ clonal expansion

Trial16-hIn patients receiving neoadjuvant immunotherapyCell metabolism, Feb 19, 2026

down: Decreases body weight-1.6 kg (95% CI -2.5 to -0.8)

down: Decreases muscle mass-1.3 kg (95% CI -2.5 to -0.2)

no change: Has no effect on fat mass-0.1 kg (95% CI -1.3 to 1.4)

Randomized trial12 weeks57 peopleBothPatient cohortsJMIR mHealth and uHealth, Jan 26, 2026

down: Decreases body mass index

Trial12 months30 people15 men and 15 women20–40 yearsIndividuals with obesityMedicina (Kaunas, Lithuania), Jan 25, 2026

down: Decreases body weight107.3 ± 17.5 kg to 100.5 ± 15.2 kg, p < 0.001

Treated cohort3 months26 peopleBothmean age 60 yearsMidlife adults; Older adults; type 2 diabetes and overweight or obesityClinical nutrition ESPEN, Jan 24, 2026

down: Decreases HbA1c−0.50 vs −0.20

down: Decreases body weight-6.51% vs -4.41%

down: Decreases body fat mass-9.39% vs -5.32%

Randomized trial12 weeks125 peopleaged 21 to 60 yearsAdults aged 21 to 60 years, diagnosed with type 2 DM, and classified as obeseEuropean journal of clinical nutrition, Jan 7, 2026

down: Decreases body weight

Randomized trial6 months10 peopleMenaverage age of 65.9 (SD 8.45) yearsOlder adults; in prostate cancer patients on active surveillanceTranslational behavioral medicine, Jan 1, 2026

down: Decreases body weight

Trialthree monthsWomen35.5-36.3 yearsObese womenLa Tunisie medicale, Dec 15, 2025

down: Decreases fasting blood glucose-2.3 mmol/L [SD 1.51 mmol/L]

down: Decreases triglyceride-1.139 mmol/L [SD 1.335 mmol/L]

up: Increases Matsuda Index80.23 [SD 70.69]

Randomized trial16 weeks63 peopleBothaverage age 36.8 yearsObesity with type 2 diabetesENDO 2025 abstract, Oct 22, 2025

down: Decreases body weightp = 0.012 for young, p = 0.011 for middle-aged

down: Decreases total cholesterolp = 0.004 for young, p = 0.0024 for middle-aged

no change: Has no effect on triglyceride

Randomized trialfive months40 peopleMen23–28 and 46–59 yearsMidlife adultsNutrition and health, Oct 15, 2025

up: Increases muscle strength

down: Decreases fat mass

down: Decreases muscle mass

Randomized trial6 months23 peopleIn overweight and class 1 obese patientsActa endocrinologica (Bucharest, Romania : 2005), Oct 3, 2025

down: Decreases metabolomic age−6.58 years/month (95% CI: −12.92, −0.23)

Randomized trial8-week31 peoplePatients with relapsing-remitting multiple sclerosisAnnals of neurology, Sep 19, 2025

no change: Has no effect on cardiometabolic health

Randomized trial3 months34 people63.6 ± 9.2 years oldOlder adults; type 2 diabetesDiabetes, obesity & metabolism, Sep 18, 2025

up: Improves cardiorespiratory fitness

down: Decreases epithelial DNA methylation biomarkers of cancer risk

up: Increases ImmuneAge

Trialsix months114 peopleWomenPostmenopausal women; BMI 25-35bioRxiv (Cold Spring Harbor Laboratory), Sep 4, 2025

down: Decreases aging-linked molecular trajectories

Trial6 months156 peopleWomen30-60 yearsMidlife adults; highly compliant participantsbioRxiv (Cold Spring Harbor Laboratory), Sep 1, 2025

no change: Has no effect on new T2 lesions

down: Decreases NEFL

down: Decreases depressive symptoms

Randomized trial18 months105 peoplePatients with relapsing-remitting multiple sclerosisBMC nutrition, Aug 20, 2025

down: Decreases body weight

down: Decreases fasting blood glucose

Trial24 weeks31 peoplePatient cohortsNutrition research and practice, Jul 25, 2025

down: Decreases binge eating

no change: Has no effect on leptin

Randomized trial12 months165 peopleBoth18–60 yearsMidlife adults; Patient cohortsNutrients, Jul 21, 2025

no change: Has no effect on mTOR

no change: Has no effect on metabolic age

Trial20 days24 peoplewomen21.29 ± 1.76 yearsYoung obese womenNutrients, May 16, 2025

down: Decreases body weight−7.7 vs −4.8 kg

Randomized trial12 months165 peopleBoth18–60 yearsMidlife adults; Patient cohortsAnnals of internal medicine, Mar 31, 2025

up: Improves cognitive functionCohen’s d = 0.58

down: Decreases insomniaCohen’s d = 0.52

Trial8-week20 peoplepredominantly female (95%)mean age of 69.7 years oldOlder adults with self-reported memory declineJournal of clinical and translational science, Dec 12, 2024

down: Decreases HOMA-IR−0.77 ± 0.81 vs −0.07 ± 1.06

no change: Has no effect on HOMA-IR−0.69 ± 0.75 vs −0.42 ± 0.92

no change: Has no effect on body weight−1.74 ± 4.81 kg vs. 0.21 ± 3.50 kg

Randomized trial26 weeks68 people21-70 yearsMidlife adults; in subjects with higher baseline HGHnpj metabolic health and disease, Oct 3, 2024

down: Lowers the risk of metabolic-associated fatty liver disease33.3% vs. 63.0%

no change: Has no effect on body weight

Randomized trial12-week period60 people31 ± 9 yearsParticipants recruited from the fatty liver obesity diagnosis and treatment centerFrontiers in nutrition, Aug 20, 2024

down: Decreases brain-age-gap estimate-2.63 vs -2.42 years

up: Improves executive function

Randomized trial8 weeks46 people60% of participants were femalesmean age 63.2 yearsIndividuals aged 55–70 years with overweight/obesity and insulin resistance who were cognitively normalCell metabolism, Jun 19, 2024

up: Increases IMRSp = 0.010

down: Decreases ICHRONp = 0.035

down: Decreases HOMA-IRmedian HOMA-IR change: intermittent fasting, −0.95 [interquartile range (IQR): −1.71, −0.61] vs. ad libitum controls, 0.05 [IQR: −0.44, 0.47]

Randomized trial26 weeks69 peoplealmost 65% of subjects were femaleaveraged 49.4 yearsIndividuals with modest elevation of low-density lipoprotein cholesterol and one or more factors of the metabolic syndromeInternational journal of cardiology. Cardiovascular risk and prevention, Sep 11, 2023

up: Increases dehydroepiandrosterone+11% MESOR

no change: Has no effect on dehydroepiandrosterone

no change: Has no effect on cortisol

Trial24-h49 people25 women and 24 menmean age 48.6 ± 12.8 yearsPatients with obesityFrontiers in nutrition, Feb 6, 2023

down: Decreases body weight

no change: Has no effect on C-reactive protein

up: Improves oral glucose tolerance test-derived insulin sensitivity index

Randomized trialsix-month50 people30 women, 20 menaged 30–65 yHealthy, overweight, or mildly obese (BMI 24.0–35.0 kg/m2), weight-stable (<2 kg weight change in the previous six months) men and womenAging biology, Jan 1, 2023

up: Increases GDF-155% more than CR70

down: Decreases body weightgreater weight loss than CR70

Randomized trial8 weeksWomenPatient cohortsObesity research & clinical practice, Dec 9, 2022

down: Decreases body weight-1.8 kg (-2.8%, p < 0.001)

down: Decreases energy intakemedian 1288.0 vs 1751.5 kcal, p < 0.001

Trial28 days52 peopleBoth44 ± 11.2 yrsMidlife adultsClinical nutrition ESPEN, Aug 17, 2022

down: Decreases effector memory T cell-4.87% (95% CI: -8.59%, -1.15%)

up: Increases naïve T cells10.11% (95% CI: 3.30, 16.92%)

down: Decreases Th1 cells-4.26% (95% CI: -7.11%, -1.40%)

Randomized trial8 weeks36 people81% female37.4 ± 7.4 yearsPeople with multiple sclerosis aged 18 to 50EBioMedicine, Jul 8, 2022

down: Decreases body weightP < .001

no change: Has no effect on mood

no change: Has no effect on cognitive function

Randomized trial8 weeks46 peopleWomenmean [SD] age 50 [9] yearsMidlife adults; women with overweight or obesityNutrition research (New York, N.Y.), Jun 24, 2021

down: Decreases HbA1c43 ± 2.7 to 41 ± 2.3 mmol/mol

down: Decreases body weightaverage 5% weight loss

Randomized trial12 weeks26 peoplemean 52 yearsMidlife adults; all participants, probiotic and placebo groups combinedNutrients, Nov 17, 2020